Edition:
India

Celyad SA (CYAD.BR)

CYAD.BR on Brussels Stock Exchange

8.95EUR
25 Feb 2020
Change (% chg)

-- (--)
Prev Close
€8.95
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
76,376
52-wk High
€20.74
52-wk Low
€7.63

Latest Key Developments (Source: Significant Developments)

Celyad: Closing Of 20 Million Dollars Global Offering
Tuesday, 17 Sep 2019 

Sept 17 (Reuters) - CELYAD SA ::ANNOUNCED ON MONDAY CLOSING OF $20 MILLION GLOBAL OFFERING.GLOBAL OFFERING OF 2,000,000 ORDINARY SHARES COMPRISED OF 1,675,000 ORDINARY SHARES IN FORM OF AMERICAN DEPOSITARY SHARES (ADSS) OFFERED IN U.S., CANADA AND CERTAIN COUNTRIES OUTSIDE OF EUROPE.PRICE PER ADS OF $10.00.GROSS PROCEEDS TO CELYAD FROM THE GLOBAL OFFERING AMOUNTED TO APPROXIMATELY $20.0 MILLION.GRANTED UNDERWRITERS 30-DAY OPTION TO PURCHASE UP TO ADDITIONAL 300,000 ORDINARY SHARES ON SAME TERMS AND CONDITIONS.  Full Article

Celyad Announces Pricing of $20.0 Million Global Offering
Thursday, 12 Sep 2019 

Sept 12 (Reuters) - CELYAD SA ::CELYAD ANNOUNCES PRICING OF $20.0 MILLION GLOBAL OFFERING.PRICING OF GLOBAL OFFERING OF 2,000,000 ORDINARY SHARES, COMPRISED OF 1,717,391 ORDINARY SHARES IN FORM OF AMERICAN DEPOSITARY SHARES (“ADSS”) OFFERED IN UNITED STATES, CANADA AND CERTAIN COUNTRIES OUTSIDE OF EUROPE.GROSS PROCEEDS TO CELYAD FROM THE GLOBAL OFFERING ARE EXPECTED TO BE APPROXIMATELY $20.0 MILLION.THE CLOSING OF THE GLOBAL OFFERING IS EXPECTED TO OCCUR ON SEPTEMBER 16, 2019, AND IS SUBJECT TO CUSTOMARY CLOSING CONDITIONS..PRICE PER ADS OF $10.00 (THE “U.S. OFFERING”), AND 282,609 ORDINARY SHARES IN EUROPE AND CERTAIN COUNTRIES OUTSIDE OF UNITED STATES AND CANADA IN CONCURRENT PRIVATE PLACEMENT AT PRICE PER SHARE OF €9.08.IN CONNECTION WITH GLOBAL OFFERING, CELYAD HAS GRANTED UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 300,000 ORDINARY SHARES (WHICH MAY BE IN THE FORM OF ADSS) ON SAME TERMS AND CONDITIONS.  Full Article

Celyad Announces Strategic Updates To The Autologous R/R Aml And Mds Program
Tuesday, 2 Jul 2019 

July 1 (Reuters) - Celyad SA ::CELYAD ANNOUNCES STRATEGIC UPDATES TO THE AUTOLOGOUS R/R AML AND MDS PROGRAM.CELYAD SA - FDA ACCEPTED INVESTIGATIONAL NEW DRUG APPLICATION TO COMMENCE CLINICAL TRIALS FOR NEXT-GENERATION, CAR-T CANDIDATE, CYAD-02.CELYAD SA - FDA AND FAMHP ACCEPTED PROPOSAL TO UTILIZE NEW, PROPRIETARY 'OPTIMAB' MANUFACTURING PROCESS FOR BOTH CYAD-01 AND CYAD-02.  Full Article

Celyad Updates On Cyad-01
Monday, 17 Jun 2019 

June 17 (Reuters) - Celyad SA ::CELYAD PRESENTS CLINICAL UPDATE FOR CYAD-01 AT 24TH CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION.PRELIMINARY DATA FROM COHORT 10 OF THINK TRIAL EVALUATING DENSER SCHEDULE OF INFUSIONS OF CYAD-01 WITHOUT PRECONDITIONING SHOWED BETTER CELL ENGRAFTMENT COMPARED TO BIWEEKLY INJECTIONS OF CYAD-01 WITHOUT PRECONDITIONING.RESULTS FROM ONGOING PHASE 1 THINK AND DEPLETHINK TRIALS EVALUATING CYAD-01 CONTINUE TO SUPPORT THERAPEUTIC CLINICAL DEVELOPMENT OF NKG2D-BASED CAR-T THERAPY PRODUCT CANDIDATE.  Full Article

Celyad Loss For The Year Narrows To 37.4 Million Euros
Friday, 29 Mar 2019 

March 28 (Reuters) - CELYAD SA ::CELYAD REPORTS BUSINESS UPDATE AND FULL YEAR 2018 FINANCIAL AND OPERATING RESULTS.FY REVENUE EUR 3.1 MILLION VERSUS EUR 3.5 MILLION YEAR AGO.LOSS FOR THE YEAR EUR 37.4 MILLION VERSUS LOSS OF EUR 56.4 MILLION YEAR AGO.WE LOOK FORWARD TO PROVIDING CLINICAL UPDATES FROM BOTH THE PHASE 1 THINK AND DEPLETHINK TRIALS THROUGHOUT 2019.WE LOOK FORWARD TO ADVANCING MULTIPLE SHRNA-BASED CAR-T PRODUCT CANDIDATES TOWARDS THE CLINIC IN 2020.TREASURY POSITION OF €49.7 MILLION ($56.9 MILLION) AT YEAR-END.FY OPERATING LOSS EXCLUDING NON-RECURRING ITEMS EUR 38.2 MILLION VERSUS LOSS OF EUR 26.6MLN YEAR AGO.  Full Article

Celyad Ended Q3 With 55.9 Million Euros In Cash, Cash Equivalents And Short-Term investments
Wednesday, 21 Nov 2018 

Nov 21 (Reuters) - CELYAD SA ::ENDED Q3 WITH EUR 55.9 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS.CONFIRMS ITS PREVIOUS GUIDANCE THAT EXISTING CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS SHOULD BE SUFFICIENT UNTIL MID-2020.  Full Article

Celyad: Update On CYAD-01 Solid Tumor Clinical Program
Friday, 9 Nov 2018 

Nov 9 (Reuters) - CELYAD SA ::STANDALONE CYAD-01 WITHOUT PRECONDITIONING LEADS TO DISEASE STABILIZATION IN THREE OUT OF 11 METASTATIC COLORECTAL CANCER (MCRC) PATIENTS IN THINK PHASE 1 TRIAL.PRELIMINARY SAFETY DATA FROM THINK CYFLU COHORT, EVALUATING CYAD-01 WITH PRECONDITIONING, REMAINS ENCOURAGING WITH IMPROVEMENT IN CYAD-01 KINETICS.OVERALL, FIVE OUT OF SEVEN (71%) PATIENTS ACHIEVED MEANINGFUL DECREASE IN BONE MARROW BLASTS.SHRINK PHASE 1 TRIAL UPDATE: INITIAL ACTIVITY RESULTS ASSESSED BY PATHOLOGICAL RESPONSE CRITERIA SHOWED ALL THREE PATIENTS ACHIEVED AN OBJECTIVE CLINICAL RESPONSE.SHRINK PHASE 1 TRIAL UPDATE: CONCURRENT TREATMENT OF CYAD-01 WITH FOLFOX CHEMOTHERAPY APPEARS TO BE WELL TOLERATED.SHRINK PHASE 1 TRIAL UPDATE: HE EXPANSION OF PERIPHERAL CYAD-01 CELLS WITH A CONCURRENT ADMINISTRATION OF FOLFOX CHEMOTHERAPY IS SIMILAR TO THE ONE OBSERVED WITH THE STANDALONE CYAD-01.SHRINK PHASE 1 TRIAL UPDATE: FULL DATA FROM THE SHRINK PHASE 1 TRIAL ARE EXPECTED IN MID-2019.THINK CYFLU PHASE 1 COHORT UPDATE: TREATMENT WITH CYAD-01 FOLLOWING STANDARD PRECONDITIONING REGIMEN OF CYFLU WAS WELL TOLERATED.THINK CYFLU PHASE 1 COHORT UPDATE: PRELIMINARY TRANSLATIONAL DATA SUGGEST AN IMPROVEMENT IN THE CELL EXPANSION OF CYAD-01 INDUCED BY THE CYFLU PRECONDITIONING..THINK CYFLU PHASE 1 COHORT UPDATE: FULL DATA FROM THE THINK CYFLU PHASE 1 COHORT ARE EXPECTED IN MID-2019..  Full Article

Celyad Appoints Filippo Petti As Chief Financial Officer
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - CELYAD SA ::CELYAD APPOINTS FILIPPO PETTI AS CHIEF FINANCIAL OFFICER.MR. PETTI’S APPOINTMENT WILL BE EFFECTIVE SEPTEMBER 3RD, 2018.MR. JEANMART REMAINING AS AN ADVISOR THROUGH DECEMBER 3(ST), 2018.  Full Article

Celyad Announces FDA Acceptance Of IND Application For CYAD-101
Tuesday, 24 Jul 2018 

July 24 (Reuters) - CELYAD SA ::CELYAD ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR CYAD-101, A FIRST-IN-CLASS NON-GENE EDITED ALLOGENEIC CAR-T CANDIDATE.FDA ACCEPTANCE OF IND FOR WORLD'S FIRST NON-GENE EDITED ALLOGENEIC CAR-T CLINICAL PROGRAM.CELYAD ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR CYAD-101, A FIRST-IN-CLASS NON-GENE EDITED ALLOGENEIC CAR-T CANDIDATE.FIRST OF A FAMILY OF NON-GENE EDITED ALLOGENEIC CAR-T, TARGETING COLORECTAL CANCER TO BUILD ON EXPERIENCE FROM SHRINK AUTOLOGOUS CAR T PROGRAM.  Full Article

Celyad Announces FDA Acceptance Of Ind Application For Cyad-101
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Celyad SA ::CELYAD ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR CYAD-101, A FIRST-IN-CLASS NON-GENE EDITED ALLOGENEIC CAR-T CANDIDATE.  Full Article